U.S. markets closed

Arrowhead Pharmaceuticals, Inc. (A2RR34.SA)

São Paulo - São Paulo Delayed Price. Currency in BRL
16.500.00 (0.00%)
At close: 04:47PM BRT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.50
Bid16.36 x N/A
Ask26.33 x N/A
Day's Range16.50 - 16.50
52 Week Range16.38 - 26.07
Avg. Volume15
Market CapN/A
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-5.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for A2RR34.SA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      PASADENA, Calif., September 27, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 26, 2023, the Company’s Board of Directors approved "inducement" grants to 47 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 81,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans an


      Insider Sell: CEO Christopher Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals Inc

      On September 18, 2023, Christopher Anzalone, the CEO of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), sold 57,755 shares of the company.

    • Business Wire

      Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

      PASADENA, Calif., September 11, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy. In an ongoing Phase 1/2 clinical trial, ARO-RAGE, Arrowhead’s investigational RNAi therapeutic for the treatment of inflammatory lung diseases, achieved mean target